More than 2.5 million bottles of prescription eye drops used to treat inflammation and allergies have been recalled in the United States after the US Food and Drug Administration (FDA) identified a possible foreign substance in the product. The recall involves multiple bottle sizes manufactured by Lupin Limited, an Indian pharmaceutical company, according to livemint.com.
The FDA conducted tests on samples of the eye drops at its laboratory in Bengaluru, India, which led to the discovery of the contamination risk. Following this, the agency issued a recall alert to remove the affected batches from the US market. The eye drops are prescribed for treating eye inflammation and allergies, making the recall significant for patients relying on this medication.
This recall highlights ongoing challenges in pharmaceutical quality control, especially for products manufactured overseas and distributed in the US. Lupin Limited is a major supplier in the generic drug market, and this incident adds to scrutiny on drug safety standards. Comparable recalls in recent years have impacted supply chains and raised concerns about contamination risks in imported medicines.
The FDA's recall notice was updated on July 9, 2026, and includes detailed batch information to help pharmacies and consumers identify affected products. The agency continues to monitor the situation to prevent further distribution of the contaminated eye drops.